162 related articles for article (PubMed ID: 36559273)
1. Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells.
Khoury A; Sakoff JA; Gilbert J; Karan S; Gordon CP; Aldrich-Wright JR
Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559273
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity.
Khoury A; Sakoff JA; Gilbert J; Scott KF; Karan S; Gordon CP; Aldrich-Wright JR
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456621
[TBL] [Abstract][Full Text] [Related]
3. Potent Chlorambucil-Platinum(IV) Prodrugs.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142383
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(iv) prodrugs as potent anticancer agents.
Deo KM; Sakoff J; Gilbert J; Zhang Y; Aldrich Wright JR
Dalton Trans; 2019 Nov; 48(46):17228-17240. PubMed ID: 31728483
[TBL] [Abstract][Full Text] [Related]
5. Platinum(IV) Derivatives of [Pt(1
Kostrhunova H; McGhie BS; Markova L; Novakova O; Kasparkova J; Aldrich-Wright JR; Brabec V
J Med Chem; 2023 Jun; 66(12):7894-7908. PubMed ID: 37285472
[TBL] [Abstract][Full Text] [Related]
6. Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296713
[TBL] [Abstract][Full Text] [Related]
7. Does cytotoxicity of metallointercalators correlate with cellular uptake or DNA affinity?
Davis KJ; Carrall JA; Lai B; Aldrich-Wright JR; Ralph SF; Dillon CT
Dalton Trans; 2012 Aug; 41(31):9417-26. PubMed ID: 22740039
[TBL] [Abstract][Full Text] [Related]
8. Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173934
[TBL] [Abstract][Full Text] [Related]
9. The in vitro renal cell toxicity of some unconventional anticancer phenanthroline-based platinum(II) complexes.
Ng NS; Wu MJ; Myers SJ; Aldrich-Wright JR
J Inorg Biochem; 2018 Feb; 179():97-106. PubMed ID: 29197671
[TBL] [Abstract][Full Text] [Related]
10. Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396859
[TBL] [Abstract][Full Text] [Related]
11. Biotinylated Pt(IV) prodrugs with elevated lipophilicity and cytotoxicity.
Spector D; Erofeev A; Gorelkin P; Skvortsov D; Trigub A; Markova A; Nikitina V; Ul'yanovskiy N; Shtil' A; Semkina A; Vlasova K; Zyk N; Majouga A; Beloglazkina E; Krasnovskaya O
Dalton Trans; 2023 Jan; 52(4):866-871. PubMed ID: 36629146
[TBL] [Abstract][Full Text] [Related]
12. Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator.
Wang S; Higgins VJ; Aldrich-Wright JR; Wu MJ
J Chem Biol; 2012 Apr; 5(2):51-61. PubMed ID: 23226166
[TBL] [Abstract][Full Text] [Related]
13. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
14. Biotinylated platinum(IV) complexes designed to target cancer cells.
Zhao J; Hua W; Xu G; Gou S
J Inorg Biochem; 2017 Nov; 176():175-180. PubMed ID: 28917640
[TBL] [Abstract][Full Text] [Related]
15. Comparative analyses of cytotoxicity and molecular mechanisms between platinum metallointercalators and cisplatin.
Wang S; Wu MJ; Higgins VJ; Aldrich-Wright JR
Metallomics; 2012 Aug; 4(9):950-9. PubMed ID: 22814756
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterisation and potent cytotoxicity of unconventional platinum(iv) complexes with modified lipophilicity.
Deo KM; Sakoff J; Gilbert J; Zhang Y; Aldrich Wright JR
Dalton Trans; 2019 Nov; 48(46):17217-17227. PubMed ID: 31729519
[TBL] [Abstract][Full Text] [Related]
17. Degradation of bidentate-coordinated platinum(II)-based DNA intercalators by reduced L-glutathione.
Kemp S; Wheate NJ; Pisani MJ; Aldrich-Wright JR
J Med Chem; 2008 May; 51(9):2787-94. PubMed ID: 18412325
[TBL] [Abstract][Full Text] [Related]
18. Probing the interaction of bisintercalating (2,2':6',2″-terpyridine)platinum(II) complexes with glutathione and rabbit plasma.
Harper BW; Morris TT; Gailer J; Aldrich-Wright JR
J Inorg Biochem; 2016 Oct; 163():95-102. PubMed ID: 27453535
[TBL] [Abstract][Full Text] [Related]
19. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
20. New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo.
Song XQ; Ma ZY; Wu YG; Dai ML; Wang DB; Xu JY; Liu Y
Eur J Med Chem; 2019 Apr; 167():377-387. PubMed ID: 30784875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
